The U.S. Food and Drug Administration (USFDA) banned the import of products from Ranbaxy’s Toansa plant in Punjab, India on 27 January 2014.
The ban was imposed on account of safety and quality concerns. USFDA sighted eight lapses in maintaining standard for banning the import from Toansa plant. These among others include presence of flies in sample storage room, un-calibrated instruments in laboratory and non-adherence to sample analysis procedure.
Citing manufacturing norm violations, the US Food and Drug Administration (USFDA) prohibited Ranbaxy Laboratories from distributing drugs produced at the Toansa unit, including medicines made by the company's Ohm Laboratories facility in New Jersey.
This is the company's fourth plant to face regulatory action from the American health regulator after Mohali, Paonta Sahib amd Dewas plants.
Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for a Japanese company Shionogi.
In 1952, Bhai Mohan Singh bought the company from his cousins Ranbir and Gurbax.
It was incorporated in 1961 with its head office in Borivalli, Mumbai, India and it went public in 1973.
It was acquired by Japanese Pharmaceutical Company Daiichi Sankyo in 2008.
In 2012, it launched India's first New Chemical Entity (NCE), Synriam TM, a new age cure for Malaria.
Ranbaxy exports its products to 125 countries with ground operations in 43 and manufacturing facilities in eight countries.